OpenAlex · Aktualisierung stündlich · Letzte Aktualisierung: 20.03.2026, 22:47

Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.

Role of AI in Pharma Sector

2025·0 Zitationen·International Journal for Research in Applied Science and Engineering TechnologyOpen Access
Volltext beim Verlag öffnen

0

Zitationen

1

Autoren

2025

Jahr

Abstract

Artificial intelligence has become one of the rapidly transformative forces in the pharma sector, also offering innovative solutions toovercome the longstanding challenges indrug discovery by the tally or analyzing the complex data set. AI finds short and accurate solutions to make the complex to simple. From the traditional method to modernization is the best example of AI. Making a personalized drug which is suitable for a person is set milestone in the Pharma sector, as it also optimizes the process of manufacturingbyensuringthequality.Whentheysupportpharmacovigilance,theythereeasilydetect adverse drug reactions. Though that leads face several challenges, such as data privacy modelling and transparency. The AI promises the Pharma sector to shape it into a more efficient, safe and patient- centered healthcare. s. In summary, there are immense possibilities with AI holds to enhance drug developmentbyimprovingefficiency, reducingcosts,andenablingmore personalizedtreatments.This review outlines the role of AI and current pharmaceutical challenges. AI has revolutionized drug discovery and development by enabling rapid and effective analysis of vast volumes of biological and chemical data during the identification of new therapeutic compounds. The algorithms developed can predict the efficacy, toxicity, and possible adverse effects of new drugs, optimize the steps involved in clinical trials, reduce associated time and costs, and facilitate the implementation of innovative drugs in the market,making iteasier to develop precise therapies tailored to the individual geneticprofile of patients. Despitesignificantadvancements,therearestill gapsintheapplicationof AI,particularlydue to the lack of comprehensive regulation. The constant evolution of this technology requires ongoing and in-depth legislative oversight to ensure its use remains safe, ethical, and free from bias. This review explores the role of AI in drug development, assessing its potential to enhance formulation,accelerate discovery,and repurpose existing medications. Ithighlights AI’s impactacross all stages, frominitialresearchtoclinicaltrials,emphasizingitsabilitytooptimizeprocesses,driveinnovation, and improve therapeutic outcomes.

Ähnliche Arbeiten

Autoren

Institutionen

Themen

Computational Drug Discovery MethodsArtificial Intelligence in Healthcare and EducationPharmacovigilance and Adverse Drug Reactions
Volltext beim Verlag öffnen